Utility of perindopril in mild-moderate heart failure in the daily clinical practice. METRICA trial;Utilidad del perindopril en insuficiencia cardíaca leve-moderada en la práctica clínica diaria. Estudio MÉTRICA

Revista Clinica Espanola

Volumn 203, Issue 1, 2003, Pages 3-9

  Barrios Alonso, V ^b   Pena Perez G ^b   Campuzano Ruiz, R ^b   Lombera Romero, F ^a   Peralta, Y ^c  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c NONE

Author keywords

Angiotensin converting enzyme inhibitors; Dose adjustment; Heart failure; Perindopril

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PERINDOPRIL; POTASSIUM; SODIUM;

ADULT; AGED; ARTICLE; CLINICAL OBSERVATION; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HEALTH CARE ORGANIZATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA AND VOMITING; TREATMENT OUTCOME; UNITED STATES;

EID: 0037226851     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13042181     Document Type: Article

References (37)

1. Cohen-Solal A, Desnos M, Kannel W, Levy D. The epidemiology of heart failure in French hospitals. Eur Heart J 2000;21:763-9.
2. Ho K, Pinsky J, Kannel W, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol 1993;22 (4 Suppl A):6A-13A.
3. Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996;46(403): 77-9.
4. Levy E. From cost of illness to cost-effectiveness in heart failure. Eur Heart J 1998;19(Suppl P):2-4.
5. McMurray J, Hart W, Rodees G. An Evaluation of the cost of heart failure to the National Health service in the UK. Br Med Econ 1993;285: 99-110.
6. The SOLVD investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
7. The CONSENSUS Trial Study Group: effects of enalapril on mortality in severe congestive heart failure. Results of the cooperative north scandinavian enalapril survival study. N Engl J Med 1987;316:303-10.
8. Pitt B, Pole-Wilson PA, Segal R, Martínez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
9. Guidelines for the evaluation and management of heart failure. Repor of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation 1995;92:2764-84.
10. The task force for the diagnosis and treatment of chronic heart failure, European society of cardiology. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
11. Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. Am J Cardiol 1999;83:1A-34A.
12. McMurray JJ. Failure to practice evidence-based medicine: why do the physicians not treat patients with heart failure. Eur Heart J 1998;19(Suppl L):L15-21.
13. Van Veldhuisen DJ, Charlesworth A, Crinjs hjgm, Lie Ki, Hampton J. Diferrences in drug treatment of chronic heart failure between european countries. Eur Heart J 1999;20:666-72.
14. O'Farnsworth TA. Angiotensin-converting enzyme inhibitors in heart failure: target dose prescription in elderly patients. Age Ageing 1998; 27:653-9.
15. Lau CP, Tse HF, Ng W, Li SK, Chan KK, Lau YK, et al. Are different angiotensin converting enzyme inhibitors identical for treatment of acute myocardial infarction? Results from the Hong Kong post-MI trial. Eur Heart J 1999;20 (abstract suppl).
16. Lopatin Y, Ivanenko, V, Statsenko. First dose hypotension of ACE inhibitors in patients with previous myocardial infarction and heart failure. Heart 2000;83(Suppl):A16.
17. McFadyen RJ, Lees KR, Reid JL. Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J 1991;66:206-11.
18. Vitovec J, Spinar J. First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparision of enalapril and perindopril. Eur J Heart Failure 2000;2:299-304.
19. Haïat R, Gallois H, Hanania G. Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril. J Cardiovasc Pharmacol 1999;33(6):953-9.
20. Manche A, Galea J, Busuttil W. Tolerance to ACE inhibitors after cardiac surgery. Eur J Cardiothoracic Surg 1999;15:55-60.
21. De Vries OJ, Janssen PAF, De Rooij S, Raymakers JA, Meyburg HJW. Blood pressure reduction after the dose of perindopril compared with captopril in elderly patients with heart failure. Age Ageing 1999;28(Suppl 2): Abstr 94.
22. Cleland JGF, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, et al. Perindopril for the elderly people with chronic heart failure: the PEP-CHF study. Eur J Heart Failure 1999;1:211-7.
23. Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 7th ed. New York: New York Heart Association; 1973.
24. a ed. Madrid: Alianza; 1994.
25. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative group on ACE inhibitor trials. JAMA 1995;273: 1450-6.
26. Edep ME, Shah NB, Tateo IM, Massie BM. Diferrences between primary care physicians and cardiologist in magement of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
27. Belloti P, Badano LP, Acquarone N, Griffo R, Pinto GL, Maggioni, et al. Specialty-related differences in the epidemiology, clinical profile, mangement and outcome of patients hospitalized for heart failure. The OSCUR study. Eur Heart J 2001;222:596-604.
28. Cleland JGF, Dargie HJ, McAlpine H, Ball SG, Morton JJ, Robertson JI, Ford I. Severe hypotension after first dose of enalapril in heart failure. Br Med J 1985;291:1309-12.
29. Packer M, Poole-Wilson PA, Armstrong PW, Cleland JGF, Horowitz JD on behalf of the ATLAS study group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999;100: 2312-8.
30. Lechat P, Garnham SP, Desche P, Bounhoure JP. Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993;126(3 part 2):798-806.
31. Bounhoure JP, Bottineau G, Lechat P, Garnham J, Lapeyre G. Value of perindopril in the treatment of chronic congestive heart failure. Clin Exp Hypertens [A] 1989;11 (Suppl 2):575-86.
32. Degaute JP, Leeman M, Desche P. Long term acceptability of perindopril: European multicenter trial on 856 patients. Am J Med 1992;92(Suppl 4B): 84S-90S.
33. Desche P, Anthony I, Lerebours G, Violet I, Robert S, Weber C. Acceptability of perindopril in mild-to-moderate chronic congestive heart failure. Am J Cardiol 1993;71:61E-8E.
34. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB, Kohn RM, et al. Adverse effects of enalapril in the studies of left ventricular dysfunction. Am Heart J 1996;131:350-5.
35. Packer M, Lee WH, Yushak M, Medina N. Comparision of captopril and enalapril in patients with severe chronic heart failure. N Engl J Med 1986;291:1309-12.
36. Osterziel KJ, Dietz R, Harder K, Kubler W. Comparision of captopril and enalapril in teartment of heart failure: influence on hemodynamics and measures of renal function. Cardiovasc Drugs Ther 1992;6:173-80.
37. Funck-Brentano C, Chatellier G, Alexandre IM. Reversible renal failure after combined treatment with enalapril and furosemide in a patient with congestive heart failure. Br Heart J 1986;55:590-8.